The "Cost of Innovation" is being slashed this year thanks to common-sense regulatory reform. In 2026, the US Biosimilars Market is benefiting from the FDA’s new "Science-First" approach to drug approvals. Historically, biosimilar developers were required to conduct massive, multi-year clinical trials to prove their product was "Equivalent" to the brand-name drug. However, as of March...